BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 22045465)

  • 1. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.
    Schwer AL; Ballonoff A; McCammon R; Rusthoven K; D'Agostino RB; Schefter TE
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):449-55. PubMed ID: 18538500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after chemoradiotherapy.
    Chao YK; Wu YC; Liu YH; Tseng CK; Chang HK; Hsieh MJ; Chu Y; Liu HP
    J Surg Oncol; 2010 Aug; 102(2):158-62. PubMed ID: 20648587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.
    Hsu PK; Huang CS; Wang BY; Wu YC; Hsu WH
    Ann Thorac Surg; 2014 May; 97(5):1734-41. PubMed ID: 24612702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
    Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.
    Vallböhmer D; Hölscher AH; DeMeester S; DeMeester T; Salo J; Peters J; Lerut T; Swisher SG; Schröder W; Bollschweiler E; Hofstetter W
    Ann Surg; 2010 Nov; 252(5):744-9. PubMed ID: 21037429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
    Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
    Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
    Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and clinical evaluation of axillary lymph node metastasis in esophageal cancer.
    Komatsu S; Ueda Y; Ichikawa D; Fujiwara H; Okamoto K; Kikuchi S; Shiozaki A; Imura K; Ohsawa R; Ochiai T; Tsubokura T; Yamagishi H
    Jpn J Clin Oncol; 2007 Apr; 37(4):314-8. PubMed ID: 17553821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.